Anti-Inflammatory Treatment of Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 17, 2017

Study Completion Date

April 17, 2017

Conditions
Schizophrenia
Interventions
DRUG

Anti-inflammatory Combination Therapy

"1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"

DRUG

Placebo

Non-medication pills; To be taken in morning and evening intervals.

Trial Locations (1)

21228

Maryland Psychiatric Research Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT01514682 - Anti-Inflammatory Treatment of Schizophrenia | Biotech Hunter | Biotech Hunter